A Marriage of HealthTech and FinTech in a Biotech driven Economy

Take a look at Healixa, Inc. (OTC Pink: EMOR)


Market corrections represent fantastic opportunities for investors that have been waiting on the sides to buy at the right time. In the U.S., at least, there has never been a time where major indices have not recovered from a market crash and subsequently made new records. 

In a recently released report on Avadel Pharmaceuticals, (NASDAQ: AVDL) H.C. Wainwright maintained a Buy rating on Avadel Pharmaceuticals, with a price target of $17.00. The company’s shares closed Tuesday at $8.02, but yesterday shot up to 9.35 closing at the high of the day. 

Currently, the analyst consensus on Avadel Pharmaceuticals is a Strong Buy with an average price target of $20.25, a 167.9% upside from current levels. In a report issued on March 1, Oppenheimer also maintained a Buy rating on the stock with a $19.00 price target.

H.C. Wainwright reiterated a buy rating on Cormedix (NASDAQ: CRMD) with a target of $10.00.  Shares were up nearly 10% yesterday again closing near the high of the day at $8.38 per share. 

Currently, the analyst consensus on Cormedix is a Strong Buy with an average price target of $19.63, a 173.0% upside from current levels.

Lastly, H.C. Wainwright maintained a Buy rating on Lumos Pharma (NASDAQ: LUMO)  today and set a price target of $34.00. The company’s shares closed last Tuesday at $12.93.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lumos Pharma with a $34.00 average price target.

Biotechs and Techs have been driving the market’s rebound beginning Tuesday March 9.  

So, what happens when you combine them?  You get a company that nobody is talking about yet and can be one of the largest winners of the year.  

Enter Healixa, Inc. (OTC Pink: EMOR).  The company announced on February 24th, a corporate name change to Healixa solidifying a position at the Healt Tech Table. 

Healixa is a technology company with assets in both healthtech and fintech.  Healixa marries code and care to create exceptional experiences in healthtech.  The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.

Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.

Over the past year, EMOR has cemented its status as an emerging market leader in healthtech.  Fueled by its recent fintech joint venture with Swys Inc, the name Healixa represents EMOR’s commitment to healing the fragmented user experience by blending the various elements of the digital assets.

Combining specific elements of the company’s healthtech and fintech assets has been Healixa’s main focus and an important accomplishment. With both industries quickly expanding, EMOR is uniquely positioned to capitalize on the convergence of two important tech segments which will present significant opportunities for Healixa’s current and future products within the marketplace.

Healixa, Inc. (OTC Pink: EMOR), recently announced the appointment of Rep. Denver Riggleman to its advisory board. 

Rep. Riggleman served as the United States Representative for Virginia’s 5th congressional district, and is an Air Force veteran and national security expert. Rep. Riggleman is also a successful businessman and co-owner of Silverback Distillery

Healixa is actively building a robust Advisory Board which will utilize its collective knowledge and expertise to provide guidance and direction to the Company’s executive team as it continues to grow and expand. Healixa highly values the broad range of experience that Rep. Riggleman brings to the Advisory Board, which include government, defense, national security and executive management. 

The marriage of healthtech and fintech could very well be where you need to be to hedge against growing inflation, and market volatility and Healixa could be the vehicle to get you that hedge.  

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material contained within this article was provided to EmergingGrowth.com by a third party, is for informational purposes only, is not the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated Two thousand nine hundred dollars in consideration for its work with Emerald Organic Products Inc. through the date this was published. EmergingGrowth.com may receive additional compensation and has received past compensation by or for this same company, details about which can be found in our full disclosure, here, https://emerginggrowth.com/6827465-3667/  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.